ArticleAmerican journal of reproductive immunology (New York, N.Y. : 1989)2026
Thrombotic Antiphospholipid Syndrome: A Long Term Follow-up of Patients With Recurrent Pregnancy Loss and Antiphospholipid Antibodies From the APS 1994 Study.
Article in American journal of reproductive immunology (New York, N.Y. : 1989), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
problemThere is a paucity of studies on the incidence and predictors of thrombotic antiphospholipid syndrome (APS) after pregnancy in patients with recurrent pregnancy loss (RPL) and antiphospholipid antibodies (aPL). This prospective study aimed to assess the long-term prognosis, including the occurrence of thrombosis and associated risk factors, in patients with aPL-positive RPL and related obstetric APS manifestations. METHOD OF STUDY: We examined patients with RPL and related obstetric APS manifestations who were positive for lupus anticoagulant (LA) based on APTT, Russell's viper venom time (RVVT), or β2glycoprotein I-dependent anticardiolipin antibody (β2GPIaCL) IgG and visited Nagoya City University Hospital from 1994 to 2019. A survey was conducted in 2024 in which patients were asked to complete a questionnaire on the development of APS manifestations based on the American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria.
resultsData of 259 of 285 patients (90.5%) who responded to the questionnaire were analysed. The median follows-up duration was 17 (4.6-31.1) years. Cumulatively, 9.6% (25/259) of patients with aPLs and 15.7% (18/114) of those with obstetric APS experienced thrombotic APS. LA-APTT, LA-RVVT, and β2GPIaCL IgG were independent predictors of thrombotic APS, with area under the curve values of 0.85 (0.73-0.97), 0.93 (0.87-0.99), and 0.80 (0.68-0.93), respectively. A history of intrauterine foetal death, early-onset preeclampsia, no live birth, thrombosis and complications of systematic lupus erythematosus, and persistent aPL were predictive of thrombotic APS.
conclusionPatients with RPL and aPL who exhibit the identified risk factors should undergo subsequent follow-up after pregnancy. Further research is required to investigate the potential for thrombosis prevention.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.